Misintu 20 mg (Mitomycin)

Fingolimod is an immunomodulating medication, mostly used for treating multiple sclerosis. Fingolimod is a sphingosine-1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction

Icatibant is a medication for the symptomatic treatment of acute attacks of hereditary angioedema in adults with C1-esterase-inhibitor deficiency.

Imatinib is an oral chemotherapy medication used to treat cancer.

Lenalidomide is a medication used to treat multiple myeloma and myelodysplastic syndromes. For MM it is used after at least one other treatment and generally together with dexamethasone.

Methotrexate is a chemotherapy agent and immune-system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancy and for medical abortions

Methotrexateis a chemotherapy agent and immune-system suppressant. It is used to treat cancer, autoimmune diseases, and ectopic pregnancy and for medical abortions

Mycophenolate Mofetil is an immunosuppressant medication used to prevent rejection following organ transplantation and to treat autoimmune conditions such as Crohn's disease and lupus.

Oxaliplatin is a cancer medication used to treat colorectal cancer. Often it is used together with fluorouracil and folinic acid in advanced cancer. It is given by injection into a vein

Protamine sulfate is a medication that is used to reverse the effects of heparin. It is specifically used in heparin overdose, in low molecular weight heparin overdose, and to reverse the effects of heparin during delivery and heart surgery. It is given by injection into a vein.

 Pemetreksed is a chemotherapy medication for the treatment of pleural mesothelioma and non-small cell lung cancer.

Temozolomide is a medication used to treat some brain tumors such as glioblastoma multiforme or anaplastic astrocytoma

Zomtu (Zoledronic Acid) Concentrated Solution for IV Infusion - Vial, 4 mg/5 ml, 4 mg/100 ml is used along with cancer chemotherapy to treat bone damage caused by multiple myeloma or by cancer that began in another part of the body but has spread to the bones. Please contact us for more information.

 

Onko Koçsel is proud that Bortezomib Injection 3.5 mg vial DCP application has been successfully accepted by EMA member countries on March, 2021. Onko Koçsel is open for collaboration within and outside EU countries.

Onko Kocsel Factory video